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Of the 38 deaths due to pneumonia during the six
weeks of the initial epidemic of the A2/Asian strain in
1957, in only two was the infection purely staphylococcal,
and an additional patient who died had mixed lesions
which appeared to be both pneumococcal and staphylo-
coccal. Apart from the four influenzal deaths, the
remainder were pneumococcal (Forbes, 1958). This pat-
tern has continued since.
The report, summarized in the same article, of L. S.
Young describing a simultaneous outbreak of infection
due to group B meningococci and influenza amongst 55
elderly women in a mental institution in Mississippi is
of interest in this context. A variety of interpretations
is possible, but by analogy it seems likely that influenza
potentiated invasion by the meningococci in a clrcum-
stance of a high carriage rate.
Influenza thus appears to be an opportunistic killer to
some extent, the ensuing mortality of an epidemic
depending on the bacterial prevalence at the time and
the availability of antibiotics.
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CONTROL of influenza is yet to be accomplished. To do
so requires the conquest of epidemics that recur with
unpredictable severity and timing-events suffered since
at least A.D. 1173 (Hirsch, 1883). To illustrate our plight,
Figure 1 records the impact of influenza upon the popu-
lation of the United States during the 36-year period
when the causal viruses could be identified (Center for
Disease Control, 1972).
Surveillance of influenza may be maintained by
tabulating monthly pneumonia-influenza death rates, or
by calculating excess mortality during epidemic periods.
Excess mortality data register the excess of an expectancy
calculated by fitting current reports to a theoretical curve
which takes into account seasonal variations and long-
term trends. This calculation for any particular epidemic
provides but a minimal estimate of the havoc of that
episode, since the contribution of the expected endemic
level of deaths and the upper confldence limit thereof
are automatically subtracted from the total. Nevertheless,
the excess mortality index has been found practical and
useful (Langmuir and Housworth, 1969).
EPIDEMIC FREQUENCY
If one looks for it, influenza is found annually in the
United States, and quite properly, pneumonia-infiuenza
deaths are reported each year (Davenport, 1958). The
peaks and areas under the curves of the monthly
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pneumonia-influenza death rates appear to have declined
somewhat gradually during the 1930's and early 1940's,
but they have remained relatively constant during the
past two decades. The decline is attributed to improved
standards of living and to development of antibacterial
therapeutics. The plateau indicates that widespread
application of speclflc counter-measures will be required
if further advances are to be made.
The majority of epidemics encountered since 1933 have
been influenza A. The current epidemic of 1973 is not
shown in Figure I, since the data are incomplete. In
this 39-year period of record, 20 clear-cut outbreaks of
influenza A have occurred. The viruses involved have been
designated A, AI, A2 and Hong Kong strains. These
designations recognize the abrupt antigenic shifting
which accompanies the emergence of a new subtype of
influenza A virus-an event which happens about every
ten years. Its importance lies in the fact that vaccine
efficacy is generally jeopardized by each major shift.
Eight epidemics of influenza B have occurred during
the same time period. Antigenic drift amongst strains
of influenza B takes place, but the degree of change is
relatively minimal, and abrupt shifts permitting separation
of strains into subtypes have not been encountered.
The high frequency of recurrence of epidemics is one
of the most outstanding characteristics of influenza. On
the average, 51'3% of the respiratory disease seasons
represented in Figure 1 were marked by epidemics of
influenza A and 20'5% by epidemics of influenza B, and
one or the other recurred in 71'8% of these respiratory
disease seasons. To consider the data in another way,
the odds are almost three to one that an epidemic of
influenza will occur yearly. It is clearly futile to hide
our heads in the sand and hope that infiuenza will go
away; it will not.
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The severity of epidemics of influenza A and B has
fluctuated widely since the early 1930's, and without
the development of clear trends we remain un'certain
what to expect next. Either total excess mortality or
excess mortality from pnaumonia-influenza may be used
to gauge the relative impact of different epidemics. The
use of total excess mortality avoids the bias of change
in fashions of reporting over time. The epidemics of
influenza A in 1936-1937 and 1943·1944 and of Asian
influenza in 1957·1958 were outstanding catastrophes, as
was that of influenza B in 1935-1936. The remainder of
the epidemics recorded, however, were far from trivial
events. For example, while the first Asian epidemic of
1957 cost 69,800 excess deaths from all causes, the remain-
ing epidemics through 1972 cost an additional 227,500
excess deaths for a total of 297,300 deaths. Truly,
that year, as they arrived at training centres and were
formed into companies. The remainder of each company
received formalinized saline. Vaccine and placebo were
allocated at random by use of the terminal digit of each
recruit's serial number. Persons reporting to sick call
with respiratory symptoms and fever were admitted to
hospital, at which time throat swabs and admission blood
samples were obtained. Convalescent samples were drawn
two weeks later. The diagnosis of influenza was made
by virus isolation, or more commonly by serological
findings. The number of persons participating in each
trial was large, generally in the thousands.
Table 1 summarizes the findings of the 14 trials carried
out over the period indicated. The prevailing virus is
designated by conventional nomenclature. Protection is
expressed as the percentage reduction in influenza found
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FIOURB 1: Pneumonia-influenza death rates by month, and excess mortality during epidemic periods, United States, 1934-
1972. (From Epidemiology Program, Center for Disease Control.)
influenza is a recurrent killer of no small proportions.
Yet death accounts for but a fraction of the total costs,
and these when added up, stagger the imagination. For
example, the relatively modest Hong Kong epidemic of
1968-1969 levied a total cost upon our population of
$3,880,030,000. At current prices, the cost of the 1957·1958
Asian epidemic would be $9,506,073,500. Fortunately there
are counter-measures.
INFLUENZA VIRUS VACCINE FIELD TRIALS RESULTS
The results of studies carried out over the past thirty
years clearly demonstrate that properly constituted
influenza virus vaccines confer a high degree of protection.
In support of this statement, many sources of data could
be used. The most extensive set are the results of field
trials carried out by the Commission on Infiuenza of the
Armed Forces Epidemiological Board in collaboration
with the United States Army. The late Dr Thomas
Francis junior designed and directed many of these care-
fully controlled studies, and kept a watchful eye upon
them until his death. The basic plan was to vaccinate
a fixed proportion of recruits with the vaccine under test
among vaccinated subjects compared with the rate
observed among controls. The results of the first two
trials were gratifying-72% protection against infiuenza A
and 92% against influenza B. The vaccine failure of 1947
is well known. Vaccination with A strains failed to
induce protective antibodies, because the surface antigens
of the prevailing Al virus had undergone major antigenic
shifting. When Al vaccine was tested in 1950, a high level
of protection was again found. With one exception, excellent
protection has been observed in all subsequent studies
with other experimental vaccines. The exception was 1955,
when the epidemic B strain of that year exhibited a
significant antigenic drift away from the 1940 B Lee
vaccine strain. Two failures in 27 years is not a bad
record when so much had to be learned by trial and
error. Considered in another way, the record for the
last 14 years has been perfect.
Note that in the 12 successful trials, 7 of the vaccines
yielded protection in the range of 80% to 90%; an
additional 5 vaccines gave protection at about the 70%
level. Such levels of protection constitute a highly signi-
ficant achievement, and they stand in sharp contrast to
the malicious, yet oft-repeated statement: "Well after
all, infiuenza virus vaccines are only about 40% to 60%
effective." Those low estimates stem in part from the
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results of studies carried out with subjects unmatched
tor age, sex, housing, etc., and in which cases are counted
by unreliable clinical criteria. Such studies yield diluted
TABLIIl 1
Ef/ieacy of Influenza Virus Vaccines, 1943 10 1969
Year Type ProtectionRate
1943 .. A 72%
1945 .. B 92%
1947 .. Al 9%
1950 .. Al 68%
1951 .. Al 75%
1953 .. Al 88%
1955 .. B 37%
1957 .. Al 82%
1957 .. A2 67%
1958 .. A2 86%
1958 .. B 83%
1960 .. A2 90%'
1968 .. A2 86%(Hong Kong)
1969 .. A2 73%(Hong Kong)
estimates of vaccine efficacy, especially when the relative
incidence of influenza is low (Stuart-Harris, 1970).
An additional factor contributing to the high efficacy
observed in these field trials is that the vaccines employed
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Army have now been adopted for protection of U.S.
civilians.
CONTROL OF INFLUENZA BY ANNUAL VACCINATION
A further demonstration of what can be accomplished
by use of potent vaccines is shown in Figure 2. The
entire U.S. Army is vaccinated against influenza annually.
The level of vaccination of civilians is unknown, but In
most years the volume of vaccine produced is insufficient
to vaccinate 10% of our population. In years of high
promotional activity there is vaccine for at best 25%.
In Figure 2, the index of involvement of the civilian
population with influenza is the excess of influenza and
pneumonia deaths plotted monthly so as to form a con-
tinuous line. The index of involvement of the Army is
the annual morbidity rate of common respiratory disease
and influenza per 1,000 average strength of Army per-
sonnel. These rates are plotted at the twenty-sixth week
of each calendar year, with the exception that in 1957
the scale is truncated. Since the indices dltrer, they cannot
be used to assess the relative impact of influenza upon
the two populations. However, because they were uniformly
applied to their respective populations, they can be used
to measure dilJerences in trends.
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FIGURE 2: Excess pneumonla, and influenza mortalttv, by four- week periods,
prevalence of A2 influenza. Astertsk indieates ineldence of common respiratory
of Army personnel.
from 122 United States cities during period of
disease and influenza pel' 1,000 average strength
were special products obtained under contract from
pharmaceutical laboratories. Invariably they contained a
considerably larger dose of antigen than was present in
vaccines released for civilian use. Fortunately, vaccines
Six sharp peaks mark the heavy involvement of the
civilian population in 1957, 1958, 1960, 1963, 1968 and
1969. A lesser degree of involvement is discernible in
several of the other years. In contrast to the civilian
36 THE MEDICAL JOURNAL OF AUSTRALIA SPECIAL SUPPLEMENT JUNE 2, 1973
experience, the incidence of common respiratory disease
and influenza encountered by the army in epidemic yea.rs
falls within the range observed in non-epidemic years.
These are opposite trends. Clearly the annual use of
influenza vaccines of adequate potency has brought
influenza under control in our Armed Forces. The pro-
nounced benefits of repeated vaccination observed in
English boarding-schools add independent confirmation of
the thesis that influenza can be controlled with vaccines
now available once the decision has been made to use
them properly (Turtle, 1968).
REQUIREMENTS FOR CONTROL OF INFLUENZA
If one concedes, then, that vaccination can control
influenza in sectors of the population, the questions that
remain with respect to total control are, "what is optimal
strategy?" and "what are the other requirements?". A
primary requirement is a change in attitude towards
vaccination against influenza. Many persons either do not
realize or else deny that influenza can be a devastating
experience, and many physicians de-emphasise vaccina-
tion against influenza, either because of lack of knowledge
concerning the benefits of vaccination or because of uncer-
tainty about the availability of vaccine (Rosenstock,
1960).
Vaccine shortage is a recurrent problem in the United
States, perpetuated by public pronouncements in which
minimal levels of vaccine efficacy are consistently cited,
the likelihood of an epidemic is depreciated or denied, and
the caveat "Beware the consequences of antigenic shift-
ing" is sounded over and over again. In response to such
tepid endorsements, manufacturers decide to make no
more vaccine in that year than they are almost certain
to sell. Programmes for education of the public and the
medical profession concerning the benefits of vaccination
are not undertaken, the reasoning being that it is unpro-
fitable to encourage vaccination with a product that will
not be available if the level of acceptance is raised. The
outcome is that for the past 15 years we have been
running in circles, without delivering a significant increase
in benefits to the people we are supposed to serve. My
concern is that, unless we break this vicious cycle and
develop now a positive philosophy and programme for
influenza control, the recurrence of a severe pandemic
like that of 1889 or 1918 would find us virtually helpless
once again.
An essential requirement for a positive programme
is the assurance of an adequate supply of vaccine at all
times. Stockpiling will be necessary to accomplish this
objective. Despite steady improvements in speed of pro-
curement of new epidemic strains and in vaccine produc-
tion, the programme of capturing the latest antigenic
variant in some unfortunate neighbour's backyard and
of mounting crash programmes to obtain adequate supplies
for oneself just does not work. Despite heroic efforts,
the record is "too little, too late" (Murray, 1969). Size
and composition of vaccine stockpiles are matters for
internal decision conditioned by national policies and
priorities. In making these decisions, the gamble must
be taken that through antigenic shifting nature mayor
may not make one's stockpile obsolete once every ten
years. I submit that nine-tenths of a loaf is better than
none.
STRATEGY FOR CONTROL OF INFLUENZA
Once an adequate supply of vaccine is made available,
the next question is how best to use it. At this point
one must decide what is meant by control of influenza.
In the U.S., the prime target has been defined as reduction
of the shocking number of influenza-associated deaths.
Persons at high risk of death during the annual periods
of prevalence of influenza can be identifled. Primarily
they are those of all ages who suffer from chronic
debilitating conditions affecting the cardiovascular or
bronchopulmonary systems, those with diabetes mellitus
or other chronic metabolic disorders, and those without
overt disease who are aged 55 years or older. Approxi-
mately 20% to 25% of our population fall into these
categories, and about 40 million doses of vaccine would
be required annually to afford protection for this sector
of our population. Since the volume of vaccine produced
annually in the United States is of the order of 20
million doses, and most of it is diverted for use in
healthy people, it is clear that we are only paying lip
service to the objective of reducing these deaths. One
would not expect that these feeble efforts would exert
a noticeable influence upon the number of influenza-
assoctated deaths which occur in the U.S., and in point
of fact they have not (Langmuir et alii, 1964). There is
now available sufficient experience with mass vaccination
programmes which could guide development of particulars
for a successful campaign against influenza. What is
missing is commitment to the task and assignment of
an appropriate priority. Once these steps have been
taken, we can honestly say that we have begun to try
to control influenza.
However, the high-r-isk groups are only a part of the
influenza problem. Their vaccination would clearly not
interrupt the course of an epidemic, since they are not
the most important spreaders. Schoolchildren are. This
cohort generally experiences the highest attack rate,
and has been incriminated as the source of transmission
from schools to homes and thence to larger social
aggregates (Jordan, 1960). Schoolchildren are readily
available for vaccination once the public has been ade-
quately prepared.
It has now been shown that vaccination of schoolchildren
exclusively will afford a high degree of protection to the
remainder of the community (Monto et alii, 1970). In the
Fall of 1968, 85% of schoolchildren enrolled in the first
12 grades at Tecumseh, Michigan, were vaccinated
against Hong Kong influenza in four days. A control
town, Adrian, was located 12 miles away. Administration
of vaccine was virtually restricted to the 3,159 Tecumseh
schoolchildren, because at that time Hong Kong vaccine
was in short supply and available only for investigational
use. Surveillance systems for disease reporting had long
been operative in both towns. Hong Kong influenza struck
Tecumseh and Adrian two weeks after vaccination had
been completed. During the ten-week epidemic period,
Adrian experienced three times as much acute respiratory
illness as did Tecumseh. The findings shown in Figure 3
demonstrate that th., benefit of vaccinating schoolchildren
extended beyond the cohort vaccinated. It would be
expected that the schoolchildren of Tecumseh would show
a lower incidence of total acute respiratory disease, and
they do; but note that, in addition, the rate of respiratory
illness in each of the other age groups is higher in
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FIGURI!I 3: Surveillance population, Tecumseh and Adrian,
Michigan: aga-speclflc weekly mean rates of respiratory
I1lness during the period of Hong Kong influenza.
COST OF INFLUENZA EPIDEMICS
Now, implementation of the strategy outlined would
of course be costly, but what are the costs of an essen-
tially do-nothing policy? Until recently there were no
answers, but some are now becoming available. Kavet,
in the U.S., has estimated certain of the costs of epidemic
influenza utilizing the Dorothy Rice model of cost-benefit
analysis (Kavet, 1972). A small portion of his findings
is reproduced below:
not have to be carried out yearly on a routine basis, but
could be postponed until times when epidemiological
intelligence gave indication of the approach of a large
outbreak. Experience over time could answer this
question.
Once vaccination against influenza becomes more widely
accepted, there will be enhanced interest on the part
of industry and of those who prefer not to be ill to have
their share in the benefits of a vaccine programme. Where
the demand for vaccine will stop is difficult to say, but
our capacity to produce vaccine would not be a limiting
factor. All the vaccine need of the U.S. discussed today
could be met by merely doubling or tripling the volume
furnished during the aix-month period in 1957 when
vaccine production was at its peak.
Adrian. The most marked difference is seen in the 20
to 29 years age group, reflecting the heavy exposure of
young adults of Adrian to their unvaccinated school-age
children.
Gratifying though this practical demonstration of the
benefits of induced herd immunity is, it must be recognized
that vaccination of schoolchildren will not completely
protect persons in high-risk categories. At Tecumseh,
viruses were isolated from a number of persons aged
over 55 years. Since death may be the consequence of
exposure of unvaccinated high-risk subjects to influenza,
vaccination of schoolchildren must be considered as an
adjunct, not as a substitute, for vaccination of the
chronically ill and the elderly.
Sixty million doses of vaccine would be needed to
provide coverage of schoolchildren in our country. I am
confident that mass vaccination of schoolchildren would
provide a dramatic advance in the control of influenza,
and that unless we take this step, efforts at total control
are futile. It is possible that vaccination in schools would
$3,242,926,000
$1,746,215,000
$1,496,711,000
$1,955,135,000
$1,568,066,000
$ 387,069,000
$1,287,791,000
$ 178,149,000
$1.109.642,000
$ 637,104,000
$ 205,382,000
$ 431,722,000
$3.880,030,000
$1,951,597,000
$1,928,433,000
Total cost:
Whole population'
Non-high-risk population
High-risk population
Direct cost:
Whole population ..
Non-high-risk population
High-risk population
Indirect cost:
Whole population:
Non-high-risk population
High-risk population
Morbidity cost:
Whole population ..
Non-high-risk population
High-risk population
Mortality cost:
Whole populatton! ..
Non-high-rlsk population
High-risk population ..
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Calculations were made with data relevant to the first
Hong Kong epidemic of 1968-1969. As seen in Figure 1.
that epidemic does not stand out as an especially' severe
one.
1 Mortality Is expressed as the present va.lue of future earnings
lost discounted at 4%.
The total cost of the epidemic was $3.880,030,000. These
are American billions, which modestly contain only 1.000
million each. l'he total cost for the non·high~risk popu-
lation was slightly higher than that for the high·risk
group. Clearly Influenza is an important problem. not
only for the elderly. but for those in the prime of life
as well. Direct costs, which relate to delivery of medical
care and to drugs. were considerable--$637.104.00o-and
the majority of these dollars were spent in taking care of
high-risk persons. Indirect costs represent an estimate of
economic loss due principally to loss of earnings. pro-
duction deficits and untimely deaths. These costs were
not startlingly different between the groups, Together
they account for the bulk of the cost of epidemic influenza
-in this example, $3.242,926,000. However. the charae-
teristics of indirect costs in these two different segments
of the population are quite different. The morbidity cost
of the non-high-risk population was $1.668,066,000. while
the mortality cost was only $178,149,000. That distribution
of costs is strikingly different for, the high-risk population
-$1,109,642,000 for mortality and only $387.069.000 for
morbidity.
The patterns of costs described are not unique to the
U.S., and represent an enormous drain upon the
economy of any country. Moreover. they are needless.
since they are preventable. Control of influenza by
appropriate vaccination programmes could be achieved by
the investment of far less than the funds now being
expended for medical services alone. These considerations.
in addition to compassion for suffering and death, ought
to motivate us as physicians and citizens to fight against
apathy and ignorance, and to get on with the job of
controlling influenza by intelligent use of the tools we
now have at hand.
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A DISCUSSION of future developments in any fleld carries
with it certain inherent elements of risk. The glowing
promises of today's newly discovered techniques or newly
proposed approaches to old problems often become only
the dim promises of the future. I would like to avoid these
pitfalls as much as possible, and simply discuss with you
what we need in the way of a better influenza vaccine,
and some of the approaches now under consideration for
producing that vaccine.
We might look upon this as an exercise in market
analysis, in which we ask ourselves what it is that the
public wants - or, to put it more bluntly, what it is that
the public can be educated to want. Since I am also a
member of the public, I have taken the liberty of listing
some of those qualities of a vaccine which would seem
to be essential If the product Is to be successful. The Ideal
vaccine should have the following characteristics.
FIrst, it must be desirable. The potential customer -
that Is, the public health authorities, the physicians, the
general public - must be convinced that it serves a need.
Second, it must be acceptable. Any discomfort and
Inconvenience - real or lmaglned- associated with taking
the vaccine must be of considerably less magnitude than
the discomfort - real or Imagined - associated with the
disease.
Third, It must be efficacious. It must provide a reasonable
degree of protection for a reasonable period of time.
Fourth, It must be available. The customer must be able
to obtain It when he needs it, and at a cost that he can
afford.
Since the onset of the Asian influenza in 1957, a
staggering 280,000 excess deaths have been associated with
• Director. Temporary address, Department of Microbiology,
Australian National University, Canberra.
Address for reprints: John Curtin School of Medical Research,
A.N.U., Canberra, A.C.T. 2600.
influenza in the United States alone; public health authori-
ties clearly recognize the need for a vaccine. The total
number of bed-days associated with infiuenza epidemics
in the U.S. is more difficult to estimate, but it may
approach 100 million in an epidemic season; the physician
clearly recognizes the need for a vaccine. The average
Individual suffers from influenza of varying severity every
four or flve or even 10 years; he may not share the same
enthusiasm for a vaccine.
In a study conducted In the U.S., just at the height of
publicity of the impending 1957 epidemic, less than 50%
of those surveyed believed that Influenza would be more
serious than the common cold. Less than 3% of the
population believed that influenza would require any
marked change in the Individual's daily activity. The
study concluded that a person would not take action to
ward oft a disease unless he believed, flrst, that he was
susceptible to it, second, that its occurrence would be
serious, and third, that effective and acceptable means
for preventing or controlling it existed and were available
to him.
To the patient with a chronic disease who has been
convinced that influenza maY be life-threatening, any
inconvenience posed by the vaccine is of little consequence;
but to the healthy and sceptical man in the street, the
30·year-old Image of a partially effective vaccine with a
high adverse reaction rate probably is not compatible with
his concept of an acceptable means of preventing a mild
disease which he may not get anyway. A new image for
the vaccine is essential.
One of the first alms in developing a new vaccine is
to make It as reaction-free as possible. During the last
few years there have, in fact, been a number of technical
improvements in the production of the aqueous vaccines.
which have led to a considerable reduction in toxicity.
These may be summarized as follows:
